niChe Lab for Stem Cell and Regenerative Medicine, Department of Biochemical Science and Technology, National Taiwan University, Taipei 10617, Taiwan.
Int J Mol Sci. 2022 Feb 25;23(5):2529. doi: 10.3390/ijms23052529.
Degenerative retinal disease is one of the major causes of vision loss around the world. The past several decades have witnessed emerging development of stem cell treatment for retinal disease. Nevertheless, sourcing stem cells remains controversial due to ethical concerns and their rarity. Furthermore, induced pluripotent stem cells (iPSCs) and mesenchymal stem cells (MSCs) are both isolated from patients' mature tissues; thus, issues such as avoiding moral controversy and adverse events related to immunosuppression and obtaining a large number of cells have opened a new era in regenerative medicine. This review focuses on the current application and development, clinical trials, and latest research of stem cell therapy, as well as its limitations and future directions.
退行性视网膜疾病是全球范围内导致视力丧失的主要原因之一。在过去的几十年中，干细胞治疗视网膜疾病的新兴发展已经得到了见证。然而，由于伦理问题和其稀有性，干细胞的来源仍然存在争议。此外，诱导多能干细胞（iPSCs）和间充质干细胞（MSCs）均从患者的成熟组织中分离出来；因此，避免道德争议和与免疫抑制相关的不良事件以及获得大量细胞等问题为再生医学开辟了一个新时代。本综述重点介绍了干细胞治疗的当前应用和发展、临床试验和最新研究，以及其局限性和未来方向。
